VIVE Stock Overview
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vivesto AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.29 |
| 52 Week High | kr0.91 |
| 52 Week Low | kr0.16 |
| Beta | 0.41 |
| 1 Month Change | -7.74% |
| 3 Month Change | -13.35% |
| 1 Year Change | -31.37% |
| 3 Year Change | -91.51% |
| 5 Year Change | -95.32% |
| Change since IPO | -98.88% |
Recent News & Updates
Shareholder Returns
| VIVE | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.6% | -0.06% | 0.9% |
| 1Y | -31.4% | -5.3% | 10.3% |
Return vs Industry: VIVE underperformed the Swedish Biotechs industry which returned -4.3% over the past year.
Return vs Market: VIVE underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| VIVE volatility | |
|---|---|
| VIVE Average Weekly Movement | 17.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: VIVE's share price has been volatile over the past 3 months.
Volatility Over Time: VIVE's weekly volatility has decreased from 38% to 18% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 14 | Erik Kinnman | www.vivesto.com |
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.
Vivesto AB Fundamentals Summary
| VIVE fundamental statistics | |
|---|---|
| Market cap | kr157.11m |
| Earnings (TTM) | -kr128.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs VIVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIVE income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr128.74m |
| Earnings | -kr128.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 23, 2024
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VIVE perform over the long term?
See historical performance and comparison